Renaissance Technologies (RenTech)'s CHRS Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 331,700 shares of Coherus Oncology, Inc. (CHRS) worth $560,573, representing 0.00% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 31 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in CHRS, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 510,628 shares. Largest reduction occurred in Q3 2025, reducing 498,825 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Coherus Oncology (CHRS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Coherus Oncology (CHRS) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +193,800 | Add 140.54% | 331,700 | $1.69 |
| Q4 2025 | +113,800 | Add 472.20% | 137,900 | $1.42 |
| Q3 2025 | -498,825 | Reduce 95.39% | 24,100 | $1.64 |
| Q2 2025 | +12,297 | Add 2.41% | 522,925 | $0.73 |
| Q1 2025 | +510,628 | New Buy | 510,628 | $0.81 |
| Q4 2024 | -432,068 | Sold Out | 0 | $0.00 |
| Q3 2024 | +37,240 | Add 9.43% | 432,068 | $1.04 |
| Q2 2024 | +242,500 | Add 159.20% | 394,828 | $1.73 |
| Q1 2024 | +152,328 | New Buy | 152,328 | $2.39 |
| Q4 2022 | -52,800 | Sold Out | 0 | $0.00 |
| Q3 2022 | -152,700 | Reduce 74.31% | 52,800 | $9.60 |
| Q2 2022 | +41,400 | Add 25.23% | 205,500 | $7.24 |
| Q1 2022 | +108,300 | Add 194.09% | 164,100 | $12.91 |
| Q4 2021 | +55,800 | New Buy | 55,800 | $15.97 |
| Q2 2021 | -230,700 | Sold Out | 0 | $0.00 |
| Q1 2021 | -30,500 | Reduce 11.68% | 230,700 | $14.61 |
| Q4 2020 | +179,300 | Add 218.93% | 261,200 | $17.38 |
| Q3 2020 | -324,200 | Reduce 79.83% | 81,900 | $18.34 |
| Q2 2020 | +326,200 | Add 408.26% | 406,100 | $17.86 |
| Q1 2020 | -48,100 | Reduce 37.58% | 79,900 | $16.22 |
| Q4 2019 | +128,000 | New Buy | 128,000 | $18.01 |
| Q4 2018 | -17,100 | Sold Out | 0 | $0.00 |
| Q3 2018 | +17,100 | New Buy | 17,100 | $16.49 |
| Q3 2017 | -21,900 | Sold Out | 0 | $0.00 |
| Q2 2017 | -91,300 | Reduce 80.65% | 21,900 | $14.34 |
| Q1 2017 | +113,200 | New Buy | 113,200 | $21.15 |
| Q3 2016 | -94,500 | Sold Out | 0 | $0.00 |
| Q2 2016 | +94,500 | New Buy | 94,500 | $16.89 |
| Q4 2015 | -85,500 | Sold Out | 0 | $0.00 |
| Q3 2015 | +44,593 | Add 109.01% | 85,500 | $20.04 |
| Q2 2015 | +40,907 | New Buy | 40,907 | $28.89 |
Renaissance Technologies (RenTech)'s Coherus Oncology Investment FAQs
Renaissance Technologies (RenTech) first purchased Coherus Oncology, Inc. (CHRS) in Q2 2015, acquiring 40,907 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Coherus Oncology, Inc. (CHRS) for 31 quarters since Q2 2015.
Renaissance Technologies (RenTech)'s largest addition to Coherus Oncology, Inc. (CHRS) was in Q1 2025, adding 510,628 shares worth $412,077.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 331,700 shares of Coherus Oncology, Inc. (CHRS), valued at approximately $560,573.
As of the Q1 2026 filing, Coherus Oncology, Inc. (CHRS) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Coherus Oncology, Inc. (CHRS) was 522,925 shares, as reported at the end of Q2 2025.